BioNTech (NASDAQ:BNTX) Trading Down 1.9%

BioNTech SE (NASDAQ:BNTX) shares dropped 1.9% during mid-day trading on Thursday . The company traded as low as $112.72 and last traded at $113.47. Approximately 408,266 shares were traded during trading, a decline of 47% from the average daily volume of 777,595 shares. The stock had previously closed at $115.62.

Analyst Ratings Changes

Several research firms recently commented on BNTX. Deutsche Bank Aktiengesellschaft raised their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and raised their target price for the stock from $91.00 to $125.00 in a research report on Monday, September 16th. HSBC raised BioNTech from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. UBS Group lifted their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, TD Cowen dropped their price target on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $124.54.

BioNTech Price Performance

The stock has a market capitalization of $26.69 billion, a PE ratio of 224.56 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The stock’s fifty day moving average is $90.81 and its 200-day moving average is $90.63.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same period in the previous year, the company earned ($0.86) earnings per share. The company’s revenue was down 23.3% compared to the same quarter last year. As a group, equities analysts predict that BioNTech SE will post -2.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its stake in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after buying an additional 150 shares in the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of BioNTech during the 4th quarter worth approximately $30,000. Covestor Ltd boosted its holdings in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares in the last quarter. Finally, Crewe Advisors LLC purchased a new position in BioNTech during the first quarter worth approximately $75,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.